Janux Therapeutics (JANX) Equity Average: 2021-2025
Historic Equity Average for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to $983.5 million.
- Janux Therapeutics' Equity Average rose 49.73% to $983.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $983.5 million, marking a year-over-year increase of 49.73%. This contributed to the annual value of $683.6 million for FY2024, which is 105.56% up from last year.
- Per Janux Therapeutics' latest filing, its Equity Average stood at $983.5 million for Q3 2025, which was down 1.79% from $1.0 billion recorded in Q2 2025.
- Janux Therapeutics' Equity Average's 5-year high stood at $1.0 billion during Q1 2025, with a 5-year trough of $305.4 million in Q2 2023.
- In the last 3 years, Janux Therapeutics' Equity Average had a median value of $656.7 million in 2024 and averaged $631.6 million.
- Its Equity Average has fluctuated over the past 5 years, first declined by 12.74% in 2023, then skyrocketed by 142.16% in 2024.
- Janux Therapeutics' Equity Average (Quarterly) stood at $371.5 million in 2021, then fell by 12.22% to $326.1 million in 2022, then increased by 6.29% to $346.6 million in 2023, then surged by 142.16% to $839.4 million in 2024, then skyrocketed by 49.73% to $983.5 million in 2025.
- Its Equity Average was $983.5 million in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.0 billion in Q1 2025.